RiOciguAt UseRs Registry
Latest Information Update: 20 Aug 2024
At a glance
- Drugs Riociguat (Primary) ; Endothelin receptor antagonists; Epoprostenol
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- Acronyms ROAR
- Sponsors Bayer
- 26 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 01 Jun 2023 Planned End Date changed from 11 Jul 2025 to 31 Dec 2025.
- 01 Jun 2023 Planned primary completion date changed from 11 Jul 2025 to 31 Dec 2025.